KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (ONC) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for BeOne Medicines (ONC) over the last 11 years, with Q3 2025 value amounting to $48.1 million.

  • BeOne Medicines' Capital Expenditures fell 6402.38% to $48.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $240.8 million, marking a year-over-year decrease of 5678.0%. This contributed to the annual value of $492.7 million for FY2024, which is 1232.13% down from last year.
  • Per BeOne Medicines' latest filing, its Capital Expenditures stood at $48.1 million for Q3 2025, which was down 6402.38% from $40.2 million recorded in Q2 2025.
  • In the past 5 years, BeOne Medicines' Capital Expenditures ranged from a high of $157.9 million in Q3 2023 and a low of $32.7 million during Q2 2022
  • Moreover, its 5-year median value for Capital Expenditures was $108.7 million (2022), whereas its average is $94.3 million.
  • Its Capital Expenditures has fluctuated over the past 5 years, first soared by 27163.84% in 2023, then plummeted by 6402.38% in 2025.
  • Quarter analysis of 5 years shows BeOne Medicines' Capital Expenditures stood at $115.0 million in 2021, then increased by 5.55% to $121.4 million in 2022, then grew by 29.34% to $157.0 million in 2023, then plummeted by 41.08% to $92.5 million in 2024, then crashed by 48.01% to $48.1 million in 2025.
  • Its last three reported values are $48.1 million in Q3 2025, $40.2 million for Q2 2025, and $60.0 million during Q1 2025.